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osting by EAbstract 1-Bromopropane was introduced as an alternative to ozone layer-depleting solvents such
as chloroﬂuorocarbons and 1,1,1-trichloroethane. However, a dozen human cases have been
reported with symptoms and signs of toxicity to 1-bromopropane including numbness, diminished
vibration sense in the lower extremities as well as ataxic gait. An epidemiological study also dem-
onstrated dose-dependent prolongation of distal latency and decrease in vibration sense in the lower
extremities. The initial animal experiments helped to identify and analyze the initial human case of
1-bromopropane toxicity. However, animal data that can explain the central nervous system disor-
ders in humans are limited. Nonetheless, animal data should be carefully interpreted especially in a
high-order function of the central nervous system or neurological signs such as ataxia that is inﬂu-
enced by fundamental anatomical/physiological differences between humans and animals. Enzy-
matic activity in the liver may explain partly the difference in the susceptibility between humans
and animals, but further studies are needed to clarify the biological factors that can explain the dif-
ference and commonality among the species.
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1-Bromopropane is a chemical that was initially used as an
intermediate for chemical synthesis. However, it has been la-
beled as a solvent since the end of 1990’s and used for clean-
ing metals including electronic parts [1] based on its less
harmful ozone layer-depletion property. However, workers
exposed to 1-bromopropane-containing solvents were re-
ported to complain of numbness, weakness, vibration sense
loss in the lower extremities, in addition to ataxic gait
[2–5]. This was later followed by an epidemiological ﬁeld
92 G. Ichihara et al.study, which showed dose-dependent neurologic deﬁcits in
workers exposed to 1-bromopropane [6]. In this regard, ani-
mal studies have played a critical role in our understanding
the causality of 1-bromopropane-related neurologic deﬁcits
in humans [5]. This review outlines the neurotoxicity of 1-
bromopropane in humans, and compares these with those
noted in the experimental animal, as well as discusses the pos-
sible mechanisms of toxic effects of 1-bromopropane.
Neurotoxicity of 1-bromopropane in humans (Tables 1 and 2)
The ﬁrst case of 1-bromopropane intoxication was reported
in New Jersey, USA [5]. A worker engaged in degreasing
of metals using solvent containing mainly 1-bromopropane,
complained of weakness of the lower extremities and right
hand, numbness, dysphagia and difﬁculty in micturition.
Nerve conduction velocity test showed prolongation of distal
latency and reduction of sensory nerve conduction velocity in
the lower extremities, but the amplitudes of the correspond-
ing motor and sensory-evoked potentials were within the
normal ranges except for mild reduction (3.1 lV) in the left
sural nerve. Gadolinium-enhanced magnetic resonance image
(MRI) of the brain showed patchy areas of increased T2 sig-
nal in the periventricular white matter. MRI of the spinal
cord showed enhancement in the neuronal region in the
proximity of the root ganglia at several thoracic and lumbar
levels. Somatosensory evoked potential test also suggested a
lesion at the dorsal column of the spinal cord or lemniscal
level. While that paper described a single case report, the
author hypothesized that the neurologic deﬁcits were due
to exposure to 1-bomopropane citing previous animal exper-
iments on 1-bromopropane neurotoxicity [7–9]. The second
report of human cases of 1-bromopropane toxicity described
three female workers who were engaged in the manufacture
of furniture in North Carolina, USA [2]. After 10-month
exposure to 1-bromopropane, one worker developed irrita-
tion of the mucosal membranes of the sinuses and throat
as well as urinary incontinence. Further exposure to 1-bro-
mopropane resulted in gait disturbances during standing
and walking. The worker also complained of numbness, dys-
esthesia in the lower limbs, numbness in the perineum,
abnormal sweating, diarrhea, headache and memory distur-
bance. The other two workers in the same factory com-
plained of similar symptoms and signs. These cases
suggested not only sensory abnormalities in the lower
extremities as reported previously [5], but also numbness in
the perineum, headache, diarrhea, urinary incontinence and
abnormal sweating.
Other similar cases were also reported in Utah [3] and in
North Carolina, USA [4]. These cases are summarized in Table
2. Numbness and decrease in vibration sense in the lower
extremities were common in these cases. Dizziness, nausea
and headache were also often reported. In Utah cases, hyper-
reﬂexia, which indicates disorders of the central nervous sys-
tem, was described in ﬁve patients out of six. On the other
hand, the ﬁrst New Jersey case showed trace to absent ankle
jerk reﬂex, neutral plantar reﬂex, and +3 for knee ankle reﬂex.
The discrepancy between the reduced ankle jerk reﬂex in the
New Jersey case and hyperreﬂexia in the Utah cases may be
explained by the degree of damage to the peripheral nerve,
which could reduce the reﬂex, but this possibility should be
examined in further studies.With regard to the electrophysiological studies, the Utah
cases did not show abnormality in conduction velocity of
the peripheral nerves, except for the motor distal latency
of the peroneal and ulnar nerves being at the upper limit of
the normal range (6.1 ms and 3.5 ms, respectively) [3]. In
comparison, a recent epidemiological study showed that
exposure to 1-bromopropane caused prolongation of tibial
distal latency and reduction of sural sensory nerve conduc-
tion velocity without signiﬁcant changes in the amplitude of
the corresponding potentials and dose-dependent diminished
vibration sense in the lower extremities [6]. The ﬁndings of
this epidemiological study [6] is in agreement with the ﬁrst
New Jersey case [5], regarding the results of the electrophys-
iological studies of lower extremities. Whether nerve conduc-
tion velocity is affected or not depends on the exposure level
and period. A slow conduction velocity and long distal la-
tency without a marked decrease in the amplitude of the cor-
responding potentials suggest demyelinating polyneuropathy,
rather than axonal polyneuropathy [10]. This interpretation is
supported also by rat experiments that showed myelin degen-
eration in the muscle branch of the posterior tibial nerve,
tibial nerve and/or peroneal nerve after exposure to 1-bromo-
propane for 12 weeks at 800 ppm [11] or for 5–7 weeks at
1000 ppm [7].
Regarding the neurobehavioral effects, the two severely
intoxicated cases out of the three North Carolina cases [2] were
depressed, but sometimes irritated and tended to get angry.
The Utah cases [3] also complained of depressive mood. One
epidemiological study showed lower scores for tension, depres-
sion, anxiety, fatigue and confusion in proﬁle of mood status
(POMS) in the exposed group than in the age-matched control
[12], but a recent epidemiological study did not show dose-
dependency in any of the POMS scores [6]. There are no epi-
demiological studies that can explain the mood status in the
above human cases. Three of the North Carolina cases [2]
and one of the Utah cases [3] complained of reduced short-
term memory and the latter was conﬁrmed by a cognitive test.
Epidemiological studies also showed lower cognitive function
[6,12].
In summary, human cases intoxicated with 1-bromopro-
pane mainly develop numbness and diminished vibration sense
in the lower extremities. One case and one epidemiological
study showed prolongation of the distal latency without
marked reduction of the amplitude of the corresponding po-
tential, suggesting myelin damage in the peripheral nerves. Re-
ﬂexes in the lower extremities were reported to be enhanced as
well as diminished, suggesting that 1-bromopropane is toxic to
the central nervous system and peripheral nerves.
Neurotoxicity of 1-bromopropane in animals (Table 3)
Using the mouse as the laboratory animal, a few studies inves-
tigated the kinetics [13], reproductive toxicity [14,15] and liver
toxicity [15,16] of 1-bromopropane. However, no studies have
provided data on neurotoxicity of 1-bromopropane in mice.
Thus, the following discussion on animal experiments on 1-
bromopropane-associated neurotoxicity is limited to rat
experiments.
Exposure of rats to 1-bromopropane induced prolongation
of motor distal latency and reduction of motor nerve conduc-
tion velocity in the tail nerve [7–9,11,17]. These results paral-
leled those of the human case that showed prolongation of
Table 1 Summary of human and epidemiological studies on 1-bromopropane neurotoxicity.
Place and workers Work and exposure period Summary of clinical signs and symptoms Reference
Human cases. New Jersey, US. Male (19-year-old) Metal stripper, degreasing, 2 months Numbness and diminished vibration sense, Elongated in distal
latency of lower extremities and decreased in sensory nerve
conduction velocity, MRI change in periventricular white
matter and in the region of neural foramen, in the proximity
of the nerve root ganglia at thoracic and lumbar levels, A
lesion at the dorsal column or lemniscal level in somatosensory-
evoked potential studies
[5]
North Carolina, US. 3 Females (30, 35, 50-year-old) Manufacturer of furniture, glue spray.
Time weighted average of 1BP: 133 ppm
(range 60–261 ppm) after improvement of
ventilation
Numbness, paresthesia/dysesthesia, diminished vibration sense
in lower extremities and perineum, diarrhea, dizziness, headache,
depression or anger, dizziness, sleep disturbance
[2]
Utah, US. 4 Females (26, 28, 29 and 43-year-old).
2 Males (16 and 46-year-old)
Manufacturer of furniture, glue spray.
The mean ambient air concentration of
1BP: 130 ppm (range 91–176 ppm). Time
weighted average of 1BP: 108 ppm (range
92–127 ppm)
Numbness, paresthesia and diminished vibration sense, hyperreﬂexia,
poor tandem gait, poor balance nausea, dizziness, nausea, headache
[3]
North Carolina, US. 3 Females (22, 28 and 42-
year-old). 1 Male (29-year-old)
Manufacturer of furniture, glue spray.
The geometric mean of 1BP for spray:
107 ppm (range 58–254 ppm) after
improvement of ventilation. Confounding
factor: high urinary arsenic levels
Numbness in lower extremities, depression, sleep disturbance,
headache, nausea, anorexia, hyperreﬂexia, ataxic gait, poor
tandem gait, ocular symptoms
[4]
New Jersey, Pennsylvania, US. Male 50-year-old.
Male 43-year-old
Degreasing (short term air sampling,
178 ppm). Dry cleaning
paresthesia, dysarthria, ataxia, confusion, dizziness, headache,
malaise, dizziness, nausea, slight tremor in upper extremity
[37]
Epidemiology. Jiangsu, China. 24 Females, 13 males Production of 1BP. ND–170 ppm Symptoms suggesting mucous irritation and adverse eﬀects on
the central nervous system. No severe chronic symptoms
suggestive of neurological damage
[38]
Epidemiology. Jiangsu, China. 23 Females, 23
non-exposed age-matched females
Production of 1BP. Geometric mean:
2.92 ppm (range 0.34–49.19 ppm)
Elongation of tibial distal latency, decrease in sural
sensory nerve conduction velocity, decrease in vibration
sense in toes. Lower scores in Digit span, Benton,
Pursuit aiming test, Tension, Depression, Anxiety,
Fatigue and Confusion of Proﬁle of Mood Status
(POMS)
[12]
Epidemiology. Jiangsu and Shandong, China.
60 Females, 26 Males. 60 Non-exposed age-matched
females. 26 Non-exposed age-matched males
Production of 1BP. 0.07–106.4 ppm
(males). 0.06–114.8 ppm (females)
Dose-dependent prolongation of tibial distal latency,
decreased vibration sense in toes, increase in LDH,
TSH and FSH in female workers
[39]
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Table 2 Comparisons of human cases intoxicated with 1-bromopropane.
Location NJ NC UT NC NJ PA
Work Degreasing Gluing Gluing Gluing Degreasing Dry cleaning
Age (years) 19 35 30 50 29 43 28 26 46 16 42 22 29 28 50 43
Gender M F F F F F F F M M F F M F M M
Exposure period 2m 12m 5m 9m 3m 3m 3m 3m 3m 3m 2w 2w 3w 3w 3y 2d
Numbness/
diminished sensation
in LEs
+ + + + + + + + +  + + + +
Paresthesia/
dysesthesia in LEs
+ + + + + + + + Nr + + + + +
Diminished
vibration sense in
LEs
+ + + + + + Nr + + Nr + +
Dysphagia + + +
Diarrhea + + + +
Dysuria or
incontinence
+ + +
Depressive mood + + + +
Dizziness/nausea + + + + Nr Nr + + Nr + + + +
Memory disturbance + + + +
Headache + + + +  Nr + + Nr + + + +
Sleep disturbance + + + + + +
Hyperreﬂexia in LEs +/ + + + + +  + +
Ataxic/unsteady gait + + + + + + +
Poor tandem gait  + + + +  + + +
LE: lower extremities, NJ: New Jersey, NC: North Carolina, UT: Utah, PA: Philadelphia, Nr: Not reported.
94 G. Ichihara et al.the distal latency in the lower extremities [5]. In other studies
[7,11], exposure of rats to 1-bromopropane also resulted in
myelin sheath degeneration in the common peroneal and tibial
nerves, which also corresponded with the prolongation of the
distal latency without reduction of amplitude of the corre-
sponding potentials in the human case [5]. Initial rat studies
[7,11] were conducted even before the ﬁrst report of the ﬁrst
human case, and thus helped understand and assess the seri-
ousness of the neurotoxicity identiﬁed in the ﬁrst human case
[5]. On the other hand, the neurotoxic effects of 1-bromopro-
pane in human cases were expected to be evident at the dorsal
column or lemniscal level based on somatosensory evoked
potentials [5]. Swelling of the preterminal axons in the gracile
nucleus of the medulla oblongata [7,11] might correspond with
the above expected lesions of the dorsal column. MRI of the
brain and spinal cord in the ﬁrst human case [5] showed abnor-
mal areas in the periventricular white matter and multiple tho-
racic levels in the areas of the neural foramina, in the
proximity of the nerve root ganglia, but to the best of our
knowledge, there are no histopathological studies in animals
that provide direct support to the human MRI changes.
The initial rat studies on dose-dependency [9,11] showed a
decrease in cerebral weight at 800 ppm, 8 h/day, 7 days/week
for 12 weeks. This decrease in cerebral weight should be noted
as a possible indicator of toxicity to the central nervous sys-
tem, given that toluene, which is known to cause atrophy in
the human brain, did not decrease any brain regions of cere-
brum, cerebellum or brainstem in rats at 1000 ppm, 8 h/day,
6 days/week for 16 weeks [18]. On the other hand, there is no
report yet of brain atrophy in human cases intoxicated with
1-bromopropane.
The initial rat studies showed pyknotic shrinkage in the cer-
ebellum after exposure to 1-bromopropane for 5–7 weeks anddegeneration of Purkinje cells in the vermis of the cerebellum
after exposure at 1500 ppm for 4 weeks. Since the morpholog-
ical changes in Purkinje cells were not evident following expo-
sure to 6800 ppm for 12 weeks, the cerebellar toxicity seems to
be limited to exposure greater than 1000 ppm. While other
groups [19,20] described ataxic gait in rats, it is difﬁcult to
compare this with the ataxic gait in humans since the 4-footed
walking rat is different from the bipedal walking human in
terms of expression of ataxia. Regarding ataxia in humans,
the authors of a case report on the four patients from North
Carolina discussed the involvement of sensory deﬁcits in ataxia
[4], but they also pointed out that the severity of ataxia seemed
out of proportion to the sensory deﬁcit. Among the four cases
reported, one individual showed positive Romberg sign, while
another showed moderate past-pointing in ﬁnger to nose test-
ing [4]. On the other hand, none of the three cases described by
our group showed any positive signs in Romberg test or ﬁnger
to nose, heel–shin, line-drawing or pronation-supination test.
Further studies are needed to localize the responsible lesion
in the brain that accounts for the ataxic gait in humans caused
by 1-bromopropane neurotoxicity.
Serial studies [19–23] using brain slices from rats exposed
to 1-bromopropane showed decreased paired-pulse inhibition
of the population spikes in the granular cells of the dentate
gyrus (DG) and hippocampus CA1, but this disinhibition
was reversible and not accompanied by morphological
changes, in contrast to kainic acid-induced neurotoxicity
[21]. Further studies are needed to interpret the disinhibitory
effects of 1-bromopropane on DG and CA1 in relation to the
neurological abnormalities in humans with 1-bromopropane
neurotoxicity.
Honma et al. [24] investigated the neurobehavioral effects
of 1-bromopropane in rats exposed to the vapor of the solvent
Neurotoxicity of 1-bromopropane 95at 10, 50, 200 and 1000 ppm for three weeks. Spontaneous
locomotor activity increased following exposure to 50 and
200 ppm, but reversed to the baseline level within 6 days after
cessation of exposure. In the open ﬁeld test, ambulation and
rearing increased at 200 ppm but defecation/urination de-
creased at 1000 ppm. In the water maze performance test,
the latency increased at days 14 and 21 at 1000 ppm, but re-
versed to the baseline level. This decrease in Water maze test
might explain the memory disturbance in human cases, but
the authors interpreted this change to be due to impaired mus-
cle system as shown by decrease in traction time at 200 and
1000 ppm, which did not reverse at day 7 after the end of
the exposure. The authors discussed the decrease in traction
time, which was more persistent than other neurobehavioral
indices, and suggested it was due to peripheral nerve toxicity
of 1-bromopropane. This change in the traction time might
correspond with the decrease in forelimb muscle strength,
which was found in our initial animal study [11]. Thus, animal
studies showed clear evidence of 1-bromopropane toxicity on
the peripheral nerves. On the other hand, these studies indicate
that the neurotoxic effects of 1-bromopropane on the central
nervous system are limited to axonal swelling of preterminal
axons in the gracile nucleus at 800 and 1000 ppm, reversible
paired pulse inhibition in DG at 400–700 ppm and CA1 at
700 ppm, increase in spontaneous locomotor activity at 50
and 200 ppm, increase in ambulation and rearing in the open
ﬁeld test at 200 ppm, increase in latency of water maze perfor-
mance at 1000 ppm, and degeneration of Purkinje cells in the
cerebellum at very high concentration of 1000–1500 ppm (Ta-
ble 3). The results of the animal studies provide experimental
support to the toxicity of 1-bromopropane on peripheral
nerves in humans. On the other hand, animal experiments on
the toxicity of 1-bromopropane on the central nervous system
are limited and further studies are needed to obtain data sup-
porting the data on humans, such as the change in brain or
spinal cord MRI or somatosensory evoked potential studies
as well as explaining the symptoms related to the central ner-
vous system, such as memory disturbance and depressive
mood in humans.
History of investigation of neurotoxicity of 1-bromopropane in
animals and human
The ﬁrst experiment that hinted to possible neurotoxicity of
1-bromopropane was originally designed to investigate possi-
ble neurotoxicity of its isomer 2-bromopropane where 1-bro-
mopropane was used as a possible negative control [7,17].
However, the results were different from the expectation that
2-bromopropane is more reactive than 1-bromopropane in
living systems, which was an assumption based on the result
of mutagenicity tests [25,26]. The initial experiments provided
the basis to suspect 1-bromopropane toxicity in the initial
group of human cases [2–5]. The ﬁrst human case was differ-
entiated from multiple sclerosis and described and analyzed
by referring to the ﬁrst animal experiments [5], although, ret-
rospectively speaking, these animal studies had several limita-
tions. For example, the methods of investigating peripheral
nerve deﬁcits in 1-bromopropane toxicity had been developed
for analysis of hexane neuropathy [27], which is known to in-
duce mainly peripheral polyneuropathy in humans, although
the distribution of sensory deﬁcits in humans and histopa-
thological features of paranodal swelling in the peripheralnerves of rats induced by hexane are quite different from
those induced by 1-bromopropane [2]. The human cases of
1-bromopropane intoxication identiﬁed after the initial ani-
mal experiments showed more obvious clinical symptoms/
signs related to the central nervous system than the hexane
intoxication cases [3]. In this regard, the initial animal exper-
iments without awareness of the human cases were more ori-
ented to the analysis of peripheral nerves than the central
nervous system.
Furthermore, after ﬁnding the human cases intoxicated
with 1-bromopropane, neuro- or glia-speciﬁc markers that
had been developed to investigate toluene toxicity [18,28] were
used to examine the effects of 1-bromopropane on the central
nervous system [29,30]. However, interpretation of the behav-
ior of such markers of neuron-speciﬁc proteins or glia-speciﬁc
proteins is still uncertain, because how these proteins are in-
volved in the toxicity of 1-bromopropane on the central ner-
vous system remains obscure. Thus, we have to ﬁnd new
biomarkers to understand the mechanism of 1-bromopropane
neurotoxicity.
Exploration of new biomarkers of central nervous system
toxicity
A previous inhalation study on the effects of 1-bromopro-
pane on two rat generations showed changes in maternal
behavior after exposure [31]. Neurobehavioral effect of 1-bro-
mopropane was also suggested by the irritation noted in
workers exposed to 1-bomopropane. A four-week rat inhala-
tion study screened the most affected areas of the brain by
quantitative real-time polymerase chain reaction (PCR) meth-
od for mRNA expression levels of various neurotransmitter
receptors [32]. The study showed reductions in the mRNA
expression levels of dopamine R2 receptor in the hippocam-
pus and 5-hydroxytryptamine receptor (5HTr)1a and 5HTr3a
in the pons-medulla oblongata at the lowest level of exposure
(400 ppm), suggesting they are the most sensitive markers to
1-bromopropane exposure, although analysis of the corre-
sponding protein levels did not conﬁrm these changes. How-
ever, at least practically, the study provides the rationale to
focus on the hippocampus in future DNA microarray and
proteomics analysis studies to identify biomarkers of central
nervous system toxicity of 1-bromopropane. Suda et al [33]
measured the neurotransmitter levels in different areas of
the brain in rats exposed for three weeks to 1-bromopropane
at 10, 50, 200 and 1000 ppm. However, their study did not
show dose-dependent changes in dopamine in any of the
investigated brain areas, although dopamine decreased signif-
icantly only at 50 ppm.
Other studies approached the neurotoxicity of 1-bromopro-
pane by analyzing its electrophysiological disinhibitory effects
in DG and CA1 of the hippocampus [19,20]. However, it is not
clear whether these electrophysiological effects are related to
the above analysis of mRNA expression of neurotransmitter
receptors. The reported electrophysiological changes were
not accompanied by morphological changes [21]. Based on sev-
eral studies, changes in the morphological structure of the cen-
tral nervous system are the most robust compared to
electrophysiological or biochemical indices. Thus, develop-
ment of biomarkers for studying the central nervous system
is important for the assessment of the risk of inhalational
chemicals on the central nervous system.
Table 3 Summary of results of animal studies on neurotoxicity of 1-bromopropane.
Exposure level Observed changes Reference
Rats, 1000 ppm, 8 h/day, 7 days/week, 5–7 weeks Increase in distal latency (DL), decrease in motor nerve conduction velocity (MCV) of tail nerve, axonal swelling in the
gracile nucleus of medulla oblongata, degeneration of myelin in the common peroneal nerve, pyknotic shrinkage of Purkinje
cells in the cerebellum
[7]
Rats, 200, 400, 800 ppm, 7 days/week, 12 weeks Dose-dependent decrease in muscle strength of fore- and hind-limbs, increase in DL, decrease in MCV of the tail nerve,
swelling of pre-terminal axons in the gracile nucleus of medulla oblongata, degeneration of myelin in muscle branch of posterior
tibial nerve and tibial nerve, irregular banding in soleus muscle, decrease in cerebral weight
[9,11]
Rats, 1500 ppm, 6 h/day, 5 days/week, 4 weeks Degeneration of Purkinje cells in the vermis and hemisphere of the cerebellum, ataxic gait [40]
Rats, 200, 400, 800 ppm, 7 days Dose-dependent decrease in cerebral and cerebellarc-enolase with a signiﬁcant change at 400 and 800 ppm, swelling of
pre-terminal axons in the gracile nucleus of medulla oblongata, degeneration of myelin in muscle branch of posterior
tibial nerve at 800 ppm
[29]
Rats, 200, 400, 800 ppm, 7 days/week, 12 weeks Dose-dependent decrease in cerebral c-enolase with a signiﬁcant change at 400 and 800 ppm [30]
Rats, 10, 50, 200, 1000 ppm, 8 h/day, 3 weeks Increase in spontaneous locomotor activity at 50 and 200 ppm (reversible). Increase in ambulation and rearing at 200 ppm.
Decrease in defecation and urination at 1000 ppm. Increase in latency for water maze performance at days 14 and 21 at
1000 ppm (reversible). Decrease in traction time at 200 and 1000 ppm (not reversed 7 days after the end of exposure).
[24]
Rats, 1500 ppm, 6 h/day, 5 days/week,
1, 3, 4 weeks
Increase in paired pulse ratios (PPRs) of population spike (PS) in granule cell layers of dentate gyrus (DG) in brain
slice obtained from the rats
[20]
Rats, 1500 ppm, 6 h/d, 5d/w, 1, 3, 4 weeks Field excitatory postsynaptic potentials (fEPSPs)/spike (E/S) potentiation, lower subthreshold of population spikes
(PSs) in DG at week 3 and 4. Decrease in paired-pulse inhibition in CA1 and DG
[19]
Rats, 800 ppm, 6 h/d, 5d/w, 8 weeks Increase in PPRs of PS in DG and CA1, increase in phosphorylated mitogen-activated protein kinase (MAPK) and total
amount of Ca+2/calmodulin-dependent kinase (CaMKII) a and b, decrease in CaMKIIb.
[22]
Rats, 700 ppm, 6 h/day, 5 days/week, 12 weeks Increase in PPRs of PS in DG and CA1 (reversible) [21]
Rats, 200 and 400 ppm, 6 h/day, 5 days/week,
12weeks. Rats, 400 ppm, 6 h/day, 5 days/week,
1, 4, 8, 12 weeks
Increase in PPRs of PS in DG at 400 ppm after 8- and 12-week exposure [23]
Rats, 400 ppm, 6 h/day, 5 days/week, 12 weeks Increase in PPRs of PS in DG at 400 ppm, decrease in mRNA expression of GABAA b3 and d receptors [41]
Rats, 400 ppm, 6 h/day, 5 days/week, 12 weeks Decrease in mRNA expression of Bcl-xL in neocortex, HIP and cerebellum [42]
Rats, 50, 200, 1000 ppm, 8 h/day, 7 days/week,
3 weeks
Two hours after the end of the last exposure: DAﬂ(STR: 50 ppm), DOPACﬂ(HIP*), 5HIAAﬂ(FC: 50, 1000 ppm,
STR: 200 and 1000 ppm), GABAﬂ(HIP*), aspartate›(HIP*, midbrain*, cerebellum*), glutamine›(HIP*, midbrain*,
cerebellum*). 19 hrs after the end of the last exposure: HVAﬂ(STR*), HVA/DAﬂ(STR*), NEﬂ(HT*), MHPGﬂ(OC*),
MHPG/NEﬂ(OC*), 5HT›(OC*), 5HIAA›(medulla oblongata*), aspartate›(OC*, HIP*, STR*, HT*, cerebellum*),
glutamateﬂ(midbrain: 50,200 ppm), glutamine›(FC*, OC*, HIP*, STR*, midbrain*, HT*, cerebellum*), GABAﬂ(FC*,
OC*, HIP*), taurineﬂ(OC*, HIP: 200 and 1000 ppm, STR*, midbrain: 50, 200 and 1000 ppm, HT*, medulla-oblongata*,
cerebellum*), methionineﬂ(HT*), cystathionine›(OC*, midbrain*, cerebellum*), cystathionineﬂ(OC: 200 ppm, HT:
50 ppm), serine›(FC*, OC*, HT*, cerebellum*), serineﬂ(midbrain: 50 and 200 ppm), threonine›(FC*, OC*, HIP*, STR*,
HT*, cerebellum*), threonineﬂ(midbrain: 50 and 200 ppm), b-alanine›(FC*, OC*, HIP*, STR*, midbrain*, HT*,
medulla oblongata*, cerebellum*)
[33]
Rats, 400, 800, 1000 ppm, 8 h/day, 7 days/week,
4 weeks
mRNA level of neurotransmitter receptors: 5HTr1aﬂ(pons-medulla: 400, 800 and 1000 ppm, cortex: 800 and 1000 ppm),
5HTr2aﬂ(HIP*, cortex: 800 ppm), 5HTr2c›(cortex*), 5HTr3aﬂ(midbrain*, pons-medulla: 400, 800 and 1000 ppm), 5HTr3a›
(amygdala: 400 and 1000 ppm), D1Rﬂ(cerebellum: 800 ppm, cortex: 800 ppm), D2Rﬂ(HIP: 400, 800 and 1000 ppm),
GABAa1ﬂ(HIP: 800 ppm, 1000 ppm, cortex: 800 ppm), GABAa2›(amygdala*)
[32]
DA: dopamine, DOPAC: 5HIAA: 5-hydroxyindoleacetic acid, GABA: gamma-amino butyric acid, HVA: homovanillic acid, NE: norepinephrine, MHPG: 4-hydroxy-3-methoxyphenyl-glycol,
5HT: 5-hydroxytryptamine (serotonin), STR: striatum, HIP: hippocampus, HT: hypothalamus, FC: frontal cortex, OC: occipital cortex, *Signiﬁcant change only at the highest level of 1000 ppm.
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Neurotoxicity of 1-bromopropane 97Mechanism of 1-bromopropane neurotoxicity
The decrease in cerebral weight and neuro-speciﬁc gamma-
enolase suggests that 1-bromopropane induces severe toxicity
of the central nervous system, though the direct action sites
of 1-bromopropane and its cellular mechanisms remain elu-
sive. Here, we focus on recent studies on the molecular mech-
anism of 1-bromopropane toxicity.
1-bromopropane is conjugated with glutathione and de-
pletes glutathione in the liver and brain, although a compen-
satory increase in glutathione was also observed in the spinal
cord and brain stem in rats [29,30]. Part of 1-bromopropane
is oxidized by cytochrome P450IIE1(CYPIIE1). Comparison
of CYPIIE1 null mice and wild type mice showed that CYP-
IIE1 enhanced the toxicity of 1-bromopropane on sperm
motility [14]. Another comparative study of three inbred
mice, C57BL/6 J, DBA/2 J and BALB/CA also showed high-
er levels of CYPIIE1 and lower levels of glutathione S-trans-
ferase (GST) and that glutathione contributes to the
hepatotoxicity of 1-bromopropane [15]. The same compara-
tive study in mice also showed higher susceptibility of the li-
ver in mice relative to rats [15], which may be explained by
the greater capacity for metabolism of 1-bromopropane via
oxidation in the B6C3F1 mouse than in F344 rat [14]. The
difference in susceptibility of the liver may be due to the
higher levels of CYP2E1 in the liver of male B6C3F1 mice
than male Wistar rats [34]. However, human cases and epide-
miological studies did not show any evidence of hepatotoxic-
ity, so it is possible that human resembles the rat more than
the mouse, with regard to hepatotoxicity [15]. The extremely
high susceptibility of the liver in mice discourages us from
increasing the exposure level of 1-bromopropane [15], result-
ing in difﬁculty in producing observable neurotoxic effects in
mice.
1-Bromopropane also produces S-propyl cyteine adduct in
neuroﬁlaments as well as globin in rats and humans, suggest-
ing alkylating effect of 1-bromoporopane on the sulfhydryl
base of the cysteine in proteins [35]. These effects explain the
result of low levels of protein bound sulfhydryl base in the
brain of intoxicated rats [29,30]. A study using the nuclear fac-
tor (erythroid-derived 2)-related factor 2 (Nrf2)-null mice
demonstrated the involvement of oxidative stress in the hepa-
totoxic effect of 1-bromopropane, but whether the same mech-
anism explains its neurotoxicity remains elusive [16]. Further
studies are needed to clarify the role of alkylation of sulfhydryl
base in the toxic effect of 1-bromopopane.Conclusions
The toxicity of 1-bromopropane was ﬁrst described in animals
[7,11,36] followed by description in human. Animal experi-
ments helped the identiﬁcation and analysis of the initial hu-
man case of 1-bromopropane toxicity [5]. On the other hand,
animal data that can explain the clinical symptoms and signs
of neurotoxicity in human cases are limited. Animal data
should be carefully interpreted especially in a high-order func-
tion of the central nervous system or neurological signs such as
ataxia, due to fundamental anatomical and physiological dif-
ferences between humans and animals. Liver enzymatic activ-
ity may explain at least in part the differences in the
susceptibility between humans and animals, but further studiesare needed to fully clarify the biological factors that explain
the difference and commonality among species.
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